Delivery Order SPE2DB24D2003-SPE2DB26FXCS4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $44,335.29 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 24, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $5,707.30 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance at the contractor's Conshohocken, Pennsylvania facility. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 28, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, fulfills this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,188.10 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a firm fixed-price procurement with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this order at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $5,997.38 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, supplying brand-name and generic...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors valued at $8,930.27 under a firm fixed-price contract type. This delivery order, issued on November 5, 2025, with an ultimate completion date of November 6, 2025, represents a non-competitive award under DLA's existing pharmaceutical supply framework. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,043.61 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of October 24, 2025. This firm fixed-price delivery order, awarded on October 23, 2025, with no set-aside designation, represents a competitively awarded transaction for pharmaceutical supply to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $20,781.90 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of June 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,061.39 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, awarded on October 27, 2025, represents a firm fixed-price delivery order with an ultimate completion date of October 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This non-set-aside award was competitively awarded to AmerisourceBergen, a major pharmaceutical...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB26FXCS4Delivery Order
The Defense Logistics Agency (DLA) awarded a $27,947.21 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of October 24, 2025. This contract was competitively awarded without set-aside designation and utilizes firm fixed pricing. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical supply requirement as part of its ongoing federal medical procurement operations supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. Repatha (evolocumab) is a PCSK9 inhibitor prescribed for cardiovascular disease management, reflecting the company's role in distributing specialty medications across multiple therapeutic domains to federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.9k | 10/23/25 |